The three-dimensional structure of human bactericidal/permeability-increasing protein: Implications for understanding protein-lipopolysaccharide interactions

Biochemical Pharmacology

Volumn 57, Issue 3, 1999, Pages 225-229

  Beamer, Lesa J ^a   Carroll, Stephen F ^b   Eisenberg, David ^c  

^a University of Missouri   (United States)

^b XOMA Corporation   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bactericidal; Inflammation; Lipopolysaccharide; LPS binding proteins; X ray crystallography

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BINDING PROTEIN; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; GRAM NEGATIVE BACTERIUM; INFLAMMATION; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; PROTEIN INTERACTION; X RAY CRYSTALLOGRAPHY;

BLOOD BACTERICIDAL ACTIVITY; CRYSTALLOGRAPHY, X-RAY; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LIPOPOLYSACCHARIDES; MODELS, MOLECULAR; PERMEABILITY; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

EID: 0032956934     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00279-2     Document Type: Article

References (34)

1. Bone R.C. The pathogenesis of sepsis. Ann Intern Med. 115:1991;457-469.
2. Wiessner W., Casey L., Zbilut J. Treatment of sepsis and septic shock A review . Heart Lung. 24:1995;380-392.
3. Tobias P.S., Soldau K., Ulevitch R.J. Isolation of a lipopolysaccharide binding acute phase reactant from rabbit serum. J Exp Med. 164:1983;777-793.
4. Schumann R., Kirschning C., Unbehaun A., Aberle H., Knopf H., Lamping N., Ulevitch R., Herrmann F. The lipopolysaccharide-binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT-3 and other cytokine-inducible nuclear proteins. Mol Cell Biol. 16:1996;3490-3503.
5. Tobias P.S., Soldau K., Gegner J.A., Mintz D., Ulevitch R.J. Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14. J Biol Chem. 270:1995;10482-10488.
6. Hailman E., Lichenstein H.S., Wurfel M.M., Miller D.S., Johnson D.A., Kelly M., Busse L.A., Zukowski M.M., Wright S.D. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med. 179:1994;269-377.
7. Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.J., Mathison J.C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 249:1990;1431-1433.
8. Mathison J.C., Tobias P.S., Wolfson E., Ulevitch R.J. Plasma lipopolysaccharide (LPS)-binding protein A key component in macrophage recognition of gram-negative LPS . J Immunol. 149:1992;200-206.
9. 23) is a universal lipopolysaccharide-binding ligand. Infect Immun. 62:1994;3564-3567.
10. Ooi C.E., Weiss J., Doerfler M.E., Elsbach P. Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils. J Exp Med. 174:1991;649-655.
11. Weiss J., Elsbach P., Olsson I., Odeberg H. Purification and characterization of a potent bacterial membrane active protein from the granules of human polymorphonuclear leukocytes. J Biol Chem. 253:1978;2664-2672.
12. White M.L., Ma J.K., Birr C.A., Trown P.W., Carroll S.F. Measurement of bactericidal/permeability-increasing protein in human body fluids by sandwich ELISA. J Immunol Methods. 167:1994;227-236.
13. Horwitz A.H., Leigh S.D., Abrahamson S., Gazzano-Santoro H., Liu P.-S., William R.E., Carroll S.F., Theofan G. Expression and characterization of cysteine-modified variants of an amino-terminal fragment of bactericidal/permeability-increasing protein. Protein Exp Purif. 8:1996;28-40.
14. von der Mohlen M.A.N., Kimmings A.N., Wedel N.J., Mevissen M.L.C.M., Jansen J., Friedmann N., Lorenz T.J., Nelson B.J., White M.L., Bauer R., Hack C.E., Eerenber A.J.M., van Deventer S.J.H. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. J Infect Dis. 172:1995;144-151.
15. Elsbach P., Weiss J. Prospects for use of recombinant BPI in the treatment of Gram-negative bacterial infections. Infect Agents Dis. 4:1995;102-109.
16. Giroir B.P., Quint P.A., Barton P., Kirsch E.A., Kitchen L., Goldstein B., Nelson B.J., Wedel N.I., Carroll S.F., Scannon P.J. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet. 350:1997;1439-1443.
17. Weiss J. Purification and assay of bactericidal/permeability-increasing protein. Methods Enzymol. 236:1994;173-196.
18. Schumann R., Rietschel E., Loppnow H. The role of CD14 and lipopolysaccharide-binding protein (LBP) in the activation of different cell types by endotoxin. Med Microbiol Immunol. 183:1994;279-297.
19. Beamer L.J., Carroll S.F., Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science. 276:1997;1861-1864.
20. Beamer L.J., Carroll S.F., Eisenberg D. The BPI/LBP family of proteins A structural analysis of conserved regions . Protein Sci. 7:1998;906-914.
21. Beamer L.J., Fischer D., Eisenberg D. Detecting distant relatives of mammalian LPS-binding and lipid transport proteins. Protein Sci. 7:1998;1643-1646.
22. Ooi C.E., Weiss J., Elsbach P., Frangione B., Mannion B. A 25-kDa NH-2 terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein. J Biol Chem. 262:1987;14891-14894.
23. Abrahamson S.L., Wu H.-M., Williams R.E., Der K., Ottah N., Little R., Gazzano-Santoro H., Theofan G., Bauer R., Leigh S., Orme A., Horwitz A.H., Carroll S.F., Dedrick R.L. Biochemical characterization of recombinant fusions of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein Implications in biological activity . J Biol Chem. 272:1997;2149-2155.
24. Iovine N.M., Elsbach P., Weiss J. An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains. Proc Natl Acad Sci USA. 94:1997;10973-10978.
25. Han J., Mathison J.C., Ulevitch R.J., Tobias P.S. Lipopolysaccharide (LPS)-binding protein, truncated at IIe-197 binds LPS but does not transfer LPS to CD14. J Biol Chem. 269:1994;8172-8175.
26. Theofan G., Horwitz A.H., Williams R.E., Liu P.-S., Chan I., Birr C., Carroll S.F., Meszaros K., Parent J.B., Kasler H., Aberle S., Trown P.W., Gazzano-Santoro H. An amino-terminal fragment of human lipopolysaccharide-binding protein retains lipid A binding but not CD14-stimulatory activity. J Immunol. 152:1994;3623-3629.
27. Tall A. Plasma lipid transfer proteins. Annu Rev Biochem. 64:1995;235-257.
28. Wurfel M.M., Kunitake S.T., Lichenstein H.S., Kane J.P., Wright S.D. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med. 180:1994;1025-1035.
29. Schromm A.B., Brandenburg K., Rietschel E.T., Flad H.-D., Carroll S.F., Seydel U. Lipopolysaccharide-binding protein mediates CD14-independent intercalation of lipopolysaccharide into phospholipid membranes. FEBS Lett. 399:1996;267-271.
30. Yu B., Hilman E., Wright S.D. Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids. J Clin Invest. 99:1997;315-324.
31. Raetz C.R.H. Biochemistry of endotoxins. Annu Rev Biochem. 59:1990;129-170.
32. 23). J Biol Chem. 269:1994;1865-1872.
33. Taylor A.H., Heavner G., Nedelman M., Sherris D., Brunt E., Knight D., Ghrayeb J. Lipopolysaccharide (LPS) neutralizing peptides reveal a lipid A binding site of LPS binding protein. J Biol Chem. 270:1995;17934-17938.
34. Lamping N., Hoess A., Yu B., Park T.C., Kirschning C.-J., Pfeil D., Reuter D., Wright S.D., Herrmann F., Schumann R.R. Effects of site-directed mutagenesis of basic residues (Arg 94, Lys 95, Lys 99) of lipopolysaccharide (LPS)-binding protein on binding and transfer of LPS and subsequent immune cell activation. J Immunol. 157:1996;4648-4656.